Clinical application of 5-HTa-3R antagonist tropisetron in chemotherapy patients

doi:10.3748/wjg.v1.i1.52

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2950)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

332

HTML

2256

Tables (1-3)

362

Sum=2950

Oct 1, 1995 (publication date) through Aug 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Oct 1, 1995; 1(1): 52-57
Published online Oct 1, 1995. doi: 10.3748/wjg.v1.i1.52

Table 1 Emetogenic potential of chemotherapeutic agents; 5 = highest, 1 = lowest[1]

Grade 5		Grade 4		Grade 3		Grade 2		Grade 1
Drug	Dose (mg/m²)	Drug	Dose (mg/m²)	Drug	Dose (mg/m²)	Drug	Dose (mg/m²)	Drug
Cisplatin	> 100	Cisplatin	50-100	Dactinomycin	> 0.3	Dactinomycin	< 0.3	Amsacrine
				Carboplatine	> 150	Altreamine		Asparaginase
				Carmustine	> 75	Carboplatin	≤ 150	Bleomycin
				Chlormethine	> 6	Carmustine	≤ 75	Etoposide
				CyClo^-		Chlormethine	≤ 6	Fluorouracil
				Phosphamide	> 50	Cisplatin	≤ 50	Mercaptopurine
				Cytarabine	> 1000	Cyclo		Methotrexate
				Dacarbazine	> 100	Phosphamide	≤ 50	Mitomycin
				Daunorubicin	> 45	Cytarabine	≤ 1000	Mitoxantrone
				Doxorubicin	> 45	Dacarbazine	≤ 100	Procarbazine
				Epirubicin	> 75	Daunorubicin	≤ 45	Teniposide
				Ifosfamide	> 1000	Doxorubicin	≤ 45	Thioguanine
						Epirubicin	≤ 75	Vinorelbine
						Fotemustine		Vinblastine
						Ifosfamide	≤ 1000	Vincristine
								Vindesine

Abbreviations: A agents are classified as Grade 1 irrespective of dose.

Table 2 Pharmacokinetic parameters of navoban in poor and extensive metabolizers, normalized for a 10 mg dose

Parameter	Extensive metabolisers		Poor metabolisers
Parameter	IV (n = 18)	Oral (n = 43)	IV (n = 36)	Oral (n = 12)
T_max (h)		2		3.6
C_max (μg/L)	84	21.7	82	29.9
AUC (μg/L·h)	239	230	1192	1579
t_1/2β (h)	7.3	8.6	30.3	41.9
V_β (L)	554		463
F (%)	100	60-100^a	100	60-100^a

^a: Dose dependent; T_max: Time to maximum plasma concentration; C_max: Maximum plasma concentration; AUC: Area under plasma concentration-time curve; t_1/2β: Terminal phase elimination half life; V_β: Volume of distribution during termination phase; F: Bioavailability.

Table 3 Intensity of delayed vomiting on days 1 and 2 after cisplatin therapy with navoban (20 courses) or metoclopramide plus lorazepam (20 courses )

Vomiting	Navoban (% of courses)	Metoclopramide (% of courses)
Day 1	n = 18	n = 19
No vomiting episodes	75	30
1 to 2 vomiting episodes	10	5
> 2 vomiting episodes	15	65
Day 2	n = 2	n = 5
No vomiting episodes	90	75
1 to 2 vomiting episodes	10	10
> 2 vomiting episodes	0	15

Citation: Xu CT, Pan BR. Clinical application of 5-HTa-3R antagonist tropisetron in chemotherapy patients. World J Gastroenterol 1995; 1(1): 52-57
URL: https://www.wjgnet.com/1007-9327/full/v1/i1/52.htm
DOI: https://dx.doi.org/10.3748/wjg.v1.i1.52